Profile of lebrikizumab and its potential in the treatment of asthma

Producción científica: Review articlerevisión exhaustiva

17 Citas (Scopus)


Interleukin (IL)-13 has been associated with multiple inflammatory features of asthma. It affects multiple cellular lines in asthma and is a key mediator in airway hyperreactivity and remodeling. Periostin, an extracellular protein, has been used as a surrogate marker of IL-13 activity and has been linked to airway remodeling by inducing subepithelial fibrosis. Lebrikizumab is a humanized monoclonal antibody that targets IL-13. Studies have demonstrated promising results with lebrikizumab therapy in asthma with regard to pulmonary function and exacerbation rates, especially on those patients with surrogate markers of T helper cell type 2-driven inflammation (ie, elevated immunoglobulin E levels, eosinophil counts, periostin levels). Lebrikizumab appears to be a safe therapy, but there are ongoing studies evaluating its efficacy and safety profile. Other therapies that target IL-13 and the receptor of IL-4/IL-13 have been studied, but future studies are needed to determine their role in the treatment of asthma.

Idioma originalEnglish (US)
Páginas (desde-hasta)87-92
Número de páginas6
PublicaciónJournal of Asthma and Allergy
EstadoPublished - ago 10 2015

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine


Profundice en los temas de investigación de 'Profile of lebrikizumab and its potential in the treatment of asthma'. En conjunto forman una huella única.

Citar esto